Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 498629130 series 3404634
Content provided by Aleksandra Zuraw, DVM, PhD, Aleksandra Zuraw, and DVM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Aleksandra Zuraw, DVM, PhD, Aleksandra Zuraw, and DVM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Will FDA rules disrupt the way we diagnose diseases?
In this episode, I break down a seismic shift in lab medicine: a federal court has vacated the FDA’s controversial rule classifying lab-developed tests (LDTs) as medical devices. This change carries serious implications for innovation, digital pathology, AI-based diagnostics, and small labs across the U.S.
🎧 What You’ll Hear:
- What LDTs are and why they matter for rare diseases and personalized medicine
- Why the FDA rule sparked backlash from the pathology community
- What the court’s decision means for AI algorithms in digital pathology
- What’s next: Will Congress revive the VALID Act?
- How this affects labs, startups, and the future of diagnostic innovation
This podcast is packed with updates every pathology professional should know. 🔍
174 episodes
))
